Boundless Bio to Participate in the Leerink Global Healthcare Conference

Core Insights - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers, specifically targeting extrachromosomal DNA (ecDNA) biology [1][3] - The company is set to participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026, in Miami, Florida [2] - Boundless Bio is developing BBI-940, a potentially first-in-class oral therapeutic candidate aimed at degrading Kinesin as an ecDNA-directed therapeutic [3] Company Overview - Boundless Bio is headquartered in San Diego, California, and aims to address the unmet needs of patients with oncogene amplified tumors, which affect 14% to 17% of cancer patients [3] - The company is dedicated to unlocking new paradigms in cancer therapeutics through its research on ecDNA [3]